A new trading day began on Tuesday, with Viking Therapeutics Inc (NASDAQ: VKTX) stock price down -4.44% from the previous day of trading, before settling in for the closing price of $29.28. VKTX’s price has ranged from $24.41 to $89.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -57.96%. With a float of $108.95 million, this company’s outstanding shares have now reached $111.57 million.
In an organization with 36 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Viking Therapeutics Inc (VKTX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Viking Therapeutics Inc is 2.94%, while institutional ownership is 73.46%. The most recent insider transaction that took place on Jan 06 ’25, was worth 8,313,601. In this transaction President & CEO of this company sold 194,490 shares at a rate of $42.75, taking the stock ownership to the 2,366,570 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Chief Operating Officer sold 54,215 for $42.75, making the entire transaction worth $2,317,599. This insider now owns 374,134 shares in total.
Viking Therapeutics Inc (VKTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -57.96% per share during the next fiscal year.
Viking Therapeutics Inc (NASDAQ: VKTX) Trading Performance Indicators
Here are Viking Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 33.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.01, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -2.16 in one year’s time.
Technical Analysis of Viking Therapeutics Inc (VKTX)
Let’s dig in a bit further. During the last 5-days, its volume was 2.76 million. That was inferior than the volume of 4.45 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 38.30%. Additionally, its Average True Range was 2.13.
During the past 100 days, Viking Therapeutics Inc’s (VKTX) raw stochastic average was set at 6.53%, which indicates a significant decrease from 50.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.92% in the past 14 days, which was lower than the 77.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.92, while its 200-day Moving Average is $50.16. However, in the short run, Viking Therapeutics Inc’s stock first resistance to watch stands at $29.11. Second resistance stands at $30.23. The third major resistance level sits at $30.91. If the price goes on to break the first support level at $27.31, it is likely to go to the next support level at $26.63. Assuming the price breaks the second support level, the third support level stands at $25.51.
Viking Therapeutics Inc (NASDAQ: VKTX) Key Stats
With a market capitalization of 3.14 billion, the company has a total of 112,248K Shares Outstanding. Currently, annual sales are 0 K while annual income is -109,960 K. The company’s previous quarter sales were 0 K while its latest quarter income was -35,420 K.
